UnknownNCT05406154

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

Studying Mantle cell lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University Third Hospital
Principal Investigator
Hongmei Jing, Professor
Peking University Third Hospital
Enrollment
60 target
Eligibility
60 years · All sexes
Timeline
2020 – 2024

Study locations (1)

Collaborators

Peking Union Medical College Hospital · The Second Affiliated Hospital of Dalian Medical University · Peking University First Hospital · Beijing Tongren Hospital · Beijing Hospital · Beijing Tsinghua Changgeng Hospital · China-Japan Friendship Hospital · 307 Hospital of PLA · Chinese PLA General Hospital · First Affiliated Hospital of Harbin Medical University · Harbin Medical University · Baotou Cancer Hospital · Beijing Shijitan Hospital, Capital Medical University · Shanxi Province Cancer Hospital · Beijing Naval General Hospital · First Hospital of China Medical University · Jilin Provincial Tumor Hospital · Shengjing Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05406154 on ClinicalTrials.gov

Other trials for Mantle cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Mantle cell lymphoma →

← Back to all trials